Why the Street is Wrong on Amylin
The strangest thing happened on Friday, a new drug with blockbuster potential gets approved and the stock of the company that discovered the drug went down. Stranger still is all the explanations given for why the stock went down. The fact of the matter is the street is dead wrong on Amylin (NASDAQ:AMLN) and this is buying opportunity if there ever was one. After reviewing the comments made...
Exenatide Approved – Why is then is Amylin taking a hit.
This morning Amylin (NASDAQ:AMLN) announced they have received approval for Exenatide. While Diabetic Investor had accurately predicted the drug would receive approval, shares of Amylin are down nearly 9% on the news. This seemingly strange reaction can be attributed to the fact that the drug was approved for use in combination with oral medications and not as a stand alone treatment. There is also some speculation that Lilly (NYSE:LLY), Amylin’s...
Novo Continues to roll
This morning Novo Nordisk (NYSE:NVO) announced first quarter 2005 results. According to the company sales of insulin analogues in North America increased by 46%, additionally Novo now holds more than 35% of the total insulin market and over 20% of the analogue market, measured by volume. This type of strong performance in North America is becoming commonplace for Novo. With Lilly (NYSE:LLY) their main competitor struggling, Novo continues to apply...
April Issue 2005
It was interesting reviewing the quarterly numbers for the companies in the blood glucose testing market. Most impressive were LifeScan’s results, compared to results from last years 1st quarter US sales rose 24%, while International sales were up an equally impressive 26%. Although the company recently had issues with their Ultra meter, during JNJ’s conference call the company stated they did not expect any adverse affects from the shipping ban...
Bug bites Animas – Threats on the horizon
This morning insulin pump maker Animas (NASDAQ:PUMP) announced a voluntary recall of approximately 2000 of the newly released IR 1250 pump. According to the company they identified a software bug related to the use of the food database. This is just the latest problem facing Animas as they FDA recently issued a sternly worded warning letter. Timing couldn’t be worse for the company as Disetronic is set to...
One down one to go
Yesterday after the market closed Amylin (NASDAQ:AMLN) announced the FDA approved Symlin for insulin using Type 1 and Type 2 diabetics. While Diabetic Investor sees Symlin as a marginal seller the approval does bode well for Amylin. As everyone knows the real gem in Amylin’s pipeline is Exenatide which is currently before the FDA awaiting its approval which is expected in late April. Given Symlin’s approval Diabetic Investor expects Exenatide...